Fig. 7
OncoAd hsa-miR-27b suppressed HCC growth in vitro and in vivo. A Schematic diagram of the structures of the OncoAd. B Hep3B cells were treated with OncoAd hsa-miR-27b and OncoAd NC at the indicated MOI. After 48 h, cell viabilities were measured by CCK-8 assays (n = 5, unpaired t-test). C Hep3B and WRL68 cells were infected with OncoAd at the indicated MOIs for 2 days. Images of cells stained with crystal violet indicated the cytopathic effect of OncoAd hsa-miR-27b and OncoAd NC. D Growth curve of subcutaneous tumours with intra-tumoural injection of PBS (n = 7), OncoAd NC (n = 7) or OncoAd hsa-miR-27b (n = 7). OncoAd were intra-tumourally injected every 2 days after inoculating subcutaneous tumours for 21 days (Day 0); PBS was injected as a control. The arrow represents the first action of intra-tumoural injection, two-way ANOVA. E and F Macroscopic images and quantification of tumour weights of the Hep3B xenografts treated with PBS (n = 7), OncoAd NC (n = 7) or OncoAd hsa-miR-27b (n = 7) at 21 days post-intra-tumoural injection, one-way ANOVA. G Representative images of H&E staining and IHC staining of the indicated protein in Hep3B xenografts; scale bar, 200 μm. Quantification of Ki-67 and p-p65-positive cells, as well as IHC scoring of TAB3 and p65 (n = 7, one-way ANOVA). B and C were repeated three times. *p < 0.05, **p < 0.01. Data are shown as mean ± SD. NC, negative control; OncoAd, oncolytic adenovirus. MOI, multiplicities of infection; ITR, inverted terminal repeat